Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer

被引:4
作者
Fromont, G
Valeri, A
Cher, M
Pontes, JE
Vallancien, G
Validire, P
Latil, A
Cussenot, O
机构
[1] Univ Paris 07, CeRePP, EA 3104, Paris, France
[2] CHU Brest, Dept Urol, Paris, France
[3] Wayne State Univ, Detroit, MI USA
[4] Inst Mutualiste Montsouris, Dept Urol, Paris, France
[5] Inst Mutualiste Montsouris, Dept Pathol, Paris, France
[6] Genopole, Urogene, Paris, France
[7] Hop Tenon, Dept Urol, F-75970 Paris, France
关键词
prostatic neoplasms; loss of heterozygosity; human chromosome 16; prostatectomy;
D O I
10.1002/pros.20304
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: Loss of heterozygosity (LOH) at 16q23.2 is an early and frequent event in prostate cancer. LOH is thought to be involved in tumor development and progression mainly through inactivation of tumor suppressor genes. However, it has been demonstrated that LOH at 16q23.2 is an independent marker of good prognosis in breast cancer. In the present study, we evaluated the clinical relevance of 16q23.2 LOH in prostate cancer, together with other LOH frequently associated with this disease. EXPERIMENTAL DESIGN: Tumoral and normal DNA were extracted from 61 radical prostatectomies, including 30 pT2 tumors with low Gleason score [5,6] (group 1), and 31 pT3 high grade (G8-9) tumors (group 2). Median follow-up after surgery was 42 months. Three patients reccured in group 1, and 20 in group 2. LOH analysis was performed using highly informative microsatellites markers, at 16q23.2, and at other chromosome loci frequently deleted in prostate cancer: 7q31, 8p22, 12p13, 13q14, and 18q21. RESULTS: LOH at 16q23.2 is associated with low stage low grade tumors and lower preoperative PSA, while LOH at 8p22 is more frequent in high stage high grade prostate cancer. In group 2, 16q23.2 LOH was the only predictor of disease-free survival in univariate and multivariate analysis, and the cumulative LOH rate was not higher in patients non-deleted for 16q23.2. CONCLUSION: These results emphasize the interest of 16q23.2 as an independent prognostic factor in high-grade prostate cancer, and suggest that this chromosomal region may contain a gene involved in tumor progression.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 22 条
[1]  
AKTONEN P, 2005, PROSTATE, V62, P267
[2]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[3]   A comprehensive genetic map of the human genome based on 5,264 microsatellites [J].
Dib, C ;
Faure, S ;
Fizames, C ;
Samson, D ;
Drouot, N ;
Vignal, A ;
Millasseau, P ;
Marc, S ;
Hazan, J ;
Seboun, E ;
Lathrop, M ;
Gyapay, G ;
Morissette, J ;
Weissenbach, J .
NATURE, 1996, 380 (6570) :152-154
[4]  
FELDSBERG J, 2004, BRAIN PATHOL, V14, P121
[5]   Allelic losses in localized prostate cancer: Association with prognostic factors [J].
Fromont, G ;
Joulin, V ;
Chantrel-Groussard, K ;
Vallancien, G ;
Guillonneau, B ;
Validire, P ;
Latil, A ;
Cussenot, O .
JOURNAL OF UROLOGY, 2003, 170 (04) :1394-1397
[6]   Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma [J].
Godfrey, TE ;
Cher, ML ;
Chhabra, V ;
Jensen, RH .
CANCER GENETICS AND CYTOGENETICS, 1997, 98 (01) :36-42
[7]  
Hansen LL, 1998, CANCER RES, V58, P2166
[8]  
Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.3.CO
[9]  
2-E
[10]   Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma [J].
Kibel, AS ;
Faith, DA ;
Bova, GS ;
Isaacs, WB .
JOURNAL OF UROLOGY, 2000, 164 (01) :192-196